Related Experiment Video
Updated: Jan 3, 2026
Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
Published on: November 26, 2018
Targeted Therapies in Chronic Lymphocytic Leukemia: Is 2 (or 3) Better Than 1?
Chaitra Ujjani1, Bruce D Cheson2
1Seattle Cancer Care Alliance, Fred Hutchinson Cancer Research Center, Seattle, WA.
Abstract:
Small molecule inhibitors, including B-cell receptor antagonists and B-cell lymphoma - 2 inhibitors, have revolutionized the treatment of chronic lymphocytic leukemia (CLL). These agents have improved outcomes for patients of all prognostic backgrounds, thus securing their role in the frontline setting. Impressive activity has been demonstrated both with monotherapy and in combination with other targeted therapeutics. The most important remaining question is whether to administer small molecule inhibitors in a sequential fashion or in combination with each other and/or anti-CD20-directed therapy. Together, a number of retrospective and prospective clinical trials have provided insight into patient outcomes with different sequencing and combination strategies. While rituximab does not appear to provide significant additional benefit to ibrutinib, the incorporation of venetoclax appears to enable a deeper response and allow for a shorter duration of therapy. How durable of a response this produces and whether patients can be effectively retreated with venetoclax remain unclear. As various targeted therapy doublets and triplets are explored, it is important to investigate whether they produce significant long-term benefits over monotherapy and whether these approaches are appropriate for all patients.
Insights
Targeted therapies like B-cell receptor antagonists and B-cell lymphoma-2 inhibitors are transforming chronic lymphocytic leukemia (CLL) treatment. Research explores optimal sequencing and combinations for improved patient outcomes.
Area of Science:
- Oncology
- Hematology
- Pharmacology
Background:
- Small molecule inhibitors have revolutionized chronic lymphocytic leukemia (CLL) treatment.
- B-cell receptor antagonists and B-cell lymphoma-2 inhibitors are now frontline therapies.
- These agents show efficacy in monotherapy and combination regimens.
Purpose of the Study:
- To evaluate optimal sequencing and combination strategies for small molecule inhibitors in CLL.
- To compare outcomes of sequential versus combined small molecule inhibitor therapy.
- To assess the role of anti-CD20 therapy in combination regimens.
Main Methods:
- Analysis of retrospective and prospective clinical trials.
- Evaluation of patient outcomes with various treatment sequencing and combination strategies.
- Comparison of monotherapy versus combination approaches.
Main Results:
- Rituximab shows limited additional benefit when combined with ibrutinib.
- Venetoclax incorporation may lead to deeper responses and shorter treatment durations.
- Long-term durability and retreatment efficacy of venetoclax require further investigation.
Conclusions:
- The optimal use of small molecule inhibitors in CLL involves careful consideration of sequencing and combinations.
- Venetoclax-based regimens show promise for deeper responses and potentially shorter therapy.
- Further research is needed to confirm long-term benefits and suitability for all CLL patients.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:27Tumor Immunotherapy
02:56Treatment Resistant Cancers